drugset / Trial / NCT00629135
Moxifloxacin Plus Metronidazole Versus Piperacillin/Tazobactam for the Treatment of Patients With Intra-abdominal Abscesses
RandomizedParallel-groupOpen-labelTreatment
Summary
The study is contemplating the antibiotic therapy of intraabdominal abscesses. These abscesses are a serious problem in surgical practice. Associated pathophysiologic effects as for example peritonitis may become life threatening or may lead to extended periods of morbidity with prolonged hospitalization. The objective of the sudy is to evaluate whether the combination of Moxifloxacin and Metronidazole is equivalent to Piperacillin / Tazobactam with regard to clinical outcome and eradication of aerobe and anaerobe pathogens in patients with intra-abdominal abscesses.
Timeline
- Start
- 2005-11-15
- Primary completion
- 2011-08-15
- Completion
- 2011-08-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Metronidazole | Small molecule | 500 mg | Intravenous |
| Subject | Moxifloxacin | Small molecule | 400 mg | Intravenous |
| Subject | Piperacillin | Small molecule | 4.5 g | Intravenous |
| Subject | Tazobactam | Small molecule | 4.5 g | Intravenous |